Biomedical Translation Fund

Up to $250 million is available from the Biomedical Translation Fund to translate Australian health and medical research into commercial reality.

 

Biomedical Translation Fund

The Biomedical Translation Fund is an equity co-investment venture capital programme announced in the National Innovation and Science Agenda to support the development of biomedical ventures in Australia. The Biomedical Translation Fund will help translate biomedical discoveries into high growth potential companies that are improving long term health benefits and national economic outcomes.

 

Objectives

The Biomedical Translation Fund (BTF) Programme policy objectives are:

  • to invest in promising biomedical discoveries and assist in their commercialisation
  • by addressing capital and management constraints, to encourage the development of companies which are commercialising biomedical discoveries.

The Australian Government will license one or more private sector fund managers and provide Commonwealth Programme Capital, to be at least matched by Private Capital raised by private sector fund managers, to establish Licensed Funds to invest in and support the development and commercialisation of Australian Biomedical Discoveries.

 

Eligible Projects

The Biomedical Translation Fund will make investments in promising discoveries, injecting the necessary funds to progress commercialisation.

A selection process will analyse the merits of proposals, including the expected costs and benefits.

 

Biomedical Translation Fund (BTF) Managers

The Biomedical Translation Fund (BTF) has announced the three experienced venture capital fund managers to help bring biomedical discoveries from Australian start-ups to market.

The fund managers will:

  • invest in promising biomedical discoveries to help commercialise them
  • address capital and management constraints to encourage the development of companies who are commercialising biomedical breakthroughs.

The three BTF managers announced are:

  • Brandon Capital Partners
  • OneVentures Management
  • BioScience Managers.

 

Eligible Applicants

The Biomedical Translation Fund focuses on supporting early stage companies that are (or will be) developing and commercialising biomedical discoveries, for the health and economic wellbeing of Australians.

Biomedical discoveries include: therapeutic, medical or pharmaceutical products, processes, services (including digital health services), technologies or procedures that represent the application and commercialisation of the outcomes of research that serve to improve health and wellbeing. It does not include alternative or complementary medicine, or traditional medicine.

At the time of the first investment, an eligible Biomedical Translation Fundcompany must have:

  • a majority of its employees and assets inside Australia, or will use the whole of the initial investment within Australia, and
  • an average annual revenue over the previous two years below $25 million per year.

 

Timing

Applications open on an ongoing basis.

 

More Information

Check out our sample application form below for the sort of information you will be required to provide.

 

Application Process

Send your applications to

Brandon Capital Partners
Alexandra Giannakopoulos
Office Manager
[email protected]
(03) 9657 0700

 

OneVentures Management
Dr Amir Zalcenstein
Investment Manager
OneVentures
[email protected]
(02) 8205 7379

 

BioScience Managers
Matt McNamara
Chief Investment Officer/Director
[email protected]
(03) 9618 8248

 

Recipients

ProTA Therapeutics Pty Ltd (OneVentures Healthcare Fund III)
OneVentures Healthcare Fund III has committed $10 million to ProTA Therapeutics to advance the development of a promising new treatments of food allergies in children and adults.

Rex Bionics (BioScience Managers Translation Fund 1)
BioScience Managers Translation Fund 1 has invested $7.5 million to Rex Bionics to develop a hands-free robotic device to help people with severe disability to walk, exercise and rehabilitate.

Saluda Medical (BioScience Managers Translation Fund 1)
BioScience Managers Translation Fund 1 has invested $3.3 million to Saluda Medical for neuromodulation technologies for people suffering from chronic back pain and other debilitating conditions.

SummatiX Pty Ltd (BioScience Managers Translation Fund 1)
BioScience Managers Translation Fund 1 has committed $10 million to SummatiX Pty Ltd for data aggregation and commercialisation services for makers of ‘smart’ medical devices.

Global Kinetics Corporation (MRCF-BTF Fund)
Brandon Capital Partners’ MRCF BTF Fund has committed $7.75 million to Global Kinetics Corporation to accelerate the development and commercialisation of a wrist-worn device that measures symptoms and provides clinical reports to assist with planning routine care for Parkinson’s patients.

BiVACOR Pty Ltd (OneVentures Healthcare Fund III)
OneVentures Healthcare Fund III has invested $2.6 million to BiVACOR, a company that is developing a rotary total artificial heart device that could provide a life-saving solution for individuals requiring a new heart.

Avita Medical Ltd (BioScience Managers Translation Fund 1)
BioScience Managers Translation Fund 1 has committed $1.5 million to Avita Medical Ltd for improved skin regeneration through a unique process using the patient’s own skin.

Aravax Pty Ltd (MRCF-BTF Fund)
Brandon Capital Partners’ MRCF BTF Fund has invested $3.45 million into Aravax Pty Ltd for a novel form of peptide immunotherapy to treat peanut allergy.

GI Therapies Pty Ltd (MRCF-BTF Fund)
Brandon Capital Partners’ MRCF BTF Fund has invested $1.3 million to GI Therapies Pty Ltd to develop a device to treat a range of gastrointestinal motility disorders.

Certa Therapeutics Pty Ltd (MRCF-BTF Fund)
Brandon Capital Partners’ MRCF-BTF Fund has committed $22 million to Certa Therapeutics to progress the clinical development of a drug to treat kidney disease.

Paragen Bio Pty Ltd (OneVentures Healthcare Fund III)
OneVentures Healthcare Fund III has committed up to $2 million to Paragen Bio Pty Ltd, a company that is developing treatments to target autoimmune diseases using the beneficial proteins found in parasitic hookworms.

2018-11-12T11:01:24+00:00November 9th, 2018|